Tag : IMATINIB

CONFERENCE UPDATE

Ponatinib + blinatumomab vs. imatinib + chemotherapy in newly diagnosed adult Ph+ ALL: First results from the GIMEMA ALL2820
The GIMEMA ALL2820 trial evaluated a chemo-free strategy with ponatinib + blinatumomab vs. imatinib + chemotherapy in adults with newly diagnosed Ph+ ALL. The initial results show that the experimental arm achieved higher complete hematologic response (CHR) and minimal residual disease (MRD) negativity, along with improved event-free survival and overall survival, and a manageable safety profile.
CONFERENCE UPDATE

Phase 3 PhALLON trial reveals high rates of MRD negativity at any time and prolonged PFS with ponatinib in patients with newly diagnosed Ph+ ALL
Ponatinib is a third-generation BCR::ABL tyrosine kinase inhibitor (TKI) that inhibits BCR::ABL1 regardless of any single resistance mutations, including T315I.